

1. Record Nr.	UNINA9910784993303321
Autore	Bogdan Boris
Titolo	Valuation in life sciences [[electronic resource] ] : a practical guide // Boris Bogdan, Ralph Villiger
Pubbl/distr/stampa	Heidelberg, : Springer, 2008
ISBN	1-281-27620-0 9786611276201 3-540-78248-6
Edizione	[2nd ed.]
Descrizione fisica	1 online resource (344 p.)
Altri autori (Persone)	VilligerRalph
Disciplina	332.63221 338.436151
Soggetti	Valuation Biotechnology industries - Finance
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Fundamentals in Life Sciences -- Basics of Valuation -- Valuation in Life Sciences -- Exercises -- Case Studies.
Sommario/riassunto	Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise valuation manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrepreneurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences projects, i.e. to license contracts, patents, and firms. We explain the fundamentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their particular interests. We describe why

valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines.

---